|
1
|
Wei J, Zou Z, Qian X, et al: ERCC1 mRNA
levels and survival of advanced gastric cancer patients treated
with a modified FOLFOX regimen. Br J Cancer. 98:1398–1402. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang TS, Ding QQ, Guo RH, Shen H, Sun J,
Lu KH, You SH, Ge HM, Shu YQ and Liu P: Expression of livin in
gastric cancer and induction of apoptosis in SGC-7901 cells by
shRNA-mediated silencing of livin gene. Biomed Pharmacother.
64:333–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hejna M, Wöhrer S, Schmidinger M and
Raderer M: Postoperative chemotherapy for gastric cancer.
Oncologist. 11:136–145. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sakuramoto S, Sasako M, Yamaguchi T, et
al: Adjuvant chemotherapy for gastric cancer with S-1, an oral
fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang ZH, Hua D and Du X: Polymorphisms in
p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer
patients treated with oxaliplatin-based adjuvant chemotherapy.
Cancer Chemother Pharmacol. 64:1001–1007. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruzzo A, Graziano F, Kawakami K, et al:
Pharmacogenetic profiling and clinical outcome of patients with
advanced gastric cancer treated with palliative chemotherapy. J
Clin Oncol. 24:1883–1891. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wöhrer SS, Raderer M and Hejna M:
Palliative chemotherapy for advanced gastric cancer. Ann Oncol.
15:1585–1595. 2004.
|
|
8
|
Chijiwa S, Masutani C, Hanaoka F, Iwai S
and Kuraoka I: Polymerization by DNA polymerase eta is blocked by
cis-diamminedichloroplatinum(II) 1,3-d(GpTpG) cross-link:
implications for cytotoxic effects in nucleotide excision
repair-negative tumor cells. Carcinogenesis. 31:388–393. 2010.
View Article : Google Scholar
|
|
9
|
Helleday T, Petermann E, Lundin C, Hodgson
B and Sharma RA: DNA repair pathways as targets for cancer therapy.
Nat Rev Cancer. 8:193–204. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kweekel DM, Gelderblom H and Guchelaar HJ:
Pharmacology of oxaliplatin and the use of pharmacogenomics to
individualize therapy. Cancer Treat Rev. 31:90–105. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rechkunova NI and Lavrik OI: Nucleotide
excision repair in higher eukaryotes: mechanism of primary damage
recognition in global genome repair. Subcell Biochem. 50:251–277.
2010. View Article : Google Scholar
|
|
12
|
Goode EL, Ulrich CM and Potter JD:
Polymorphisms in DNA repair genes and associations with cancer
risk. Cancer Epidemiol Biomarkers Prev. 11:1513–1530.
2002.PubMed/NCBI
|
|
13
|
Friedberg EC: How nucleotide excision
repair protects against cancer. Nat Rev Cancer. 1:22–33. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: the role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao H, Wang LE, Li D, Chamberlain RM,
Sturgis EM and Wei Q: Genotypes and haplotypes of ERCC1 and
ERCC2/XPD genes predict levels of benzo[a]pyrene diol
epoxide-induced DNA adducts in cultured primary lymphocytes from
healthy individuals: a genotype-phenotype correlation analysis.
Carcinogenesis. 29:1560–1566. 2008.PubMed/NCBI
|
|
16
|
Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu
L, Wang T and Liu B: ERCC1 and BRCA1 mRNA expression levels in
metastatic malignant effusions is associated with chemosensitivity
to cisplatin and/or docetaxel. BMC Cancer. 8:972008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Halder J, Kamat AA, Landen CN Jr, et al:
Focal adhesion kinase targeting using in vivo short interfering RNA
delivery in neutral liposomes for ovarian carcinoma therapy. Clin
Cancer Res. 12:4916–4924. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hannon GJ and Rossi JJ: Unlocking the
potential of the human genome with RNA interference. Nature.
431:371–378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Snygg AS and Elmroth SK: Expanding the
chemical nature of siRNAs: oxaliplatin as metalation reagent.
Biochem Biophys Res Commun. 379:186–190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ajani JA: Evolving chemotherapy for
advanced gastric cancer. Oncologist. 10(Suppl 3): 49–58. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park DJ and Lenz HJ: Determinants of
chemosensitivity in gastric cancer. Curr Opin Pharmacol. 6:337–344.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kang HC, Kim IJ, Park HW, Jang SG, Ahn SA,
Yoon SN, Chang HJ, Yoo BC and Park JG: Regulation of MDK expression
in human cancer cells modulates sensitivities to various anticancer
drugs: MDK overexpression confers to a multi-drug resistance.
Cancer Lett. 247:40–47. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miyashita H, Nitta Y, Mori S, et al:
Expression of copper-transporting P-type adenosine triphosphatase
(ATP7B) as a chemoresistance marker in human oral squamous cell
carcinoma treated with cisplatin. Oral Oncol. 39:157–162. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakayama K, Kanzaki A, Ogawa K, Miyazaki
K, Neamati N and Takebayashi Y: Copper-transporting P-type
adenosine triphosphatase (ATP7B) as a cisplatin based
chemoresistance marker in ovarian carcinoma: comparative analysis
with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer.
101:488–495. 2002. View Article : Google Scholar
|
|
25
|
Johnson NP, Hoeschele JD and Rahn RO:
Kinetic analysis of the in vitro binding of radioactive cis- and
trans-dichlorodiammineplatinum(II) to DNA. Chem Biol Interact.
30:151–169. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marcuello E, Altés A, del Rio E, César A,
Menoyo A and Baiget M: Single nucleotide polymorphism in the 5′
tandem repeat sequences of thymidylate synthase gene predicts for
response to fluorouracil-based chemotherapy in advanced colorectal
cancer patients. Int J Cancer. 112:733–737. 2004.
|
|
27
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park CH, Bessho T, Matsunaga T and Sancar
A: Purification and characterization of the XPF-ERCC1 complex of
human DNA repair excision nuclease. J Biol Chem. 270:22657–22660.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu
ZH, Song MX and Zhou XK: ERCC1 polymorphism, expression and
clinical outcome of oxaliplatin-based adjuvant chemotherapy in
gastric cancer. World J Gastroenterol. 14:6401–6407. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tavernarakis N, Wang SL, Dorovkov M,
Ryazanov A and Driscoll M: Heritable and inducible genetic
interference by double-stranded RNA encoded by transgenes. Nat
Genet. 24:180–183. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hannon GJ: RNA interference. Nature.
418:244–251. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang H: RNAi-mediated knockdown of target
genes: a promising strategy for pancreatic cancer research. Cancer
Gene Ther. 14:677–685. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shao Y, Chan CY, Maliyekkel A, Lawrence
CE, Roninson IB and Ding Y: Effect of target secondary structure on
RNAi efficiency. RNA. 13:1631–1640. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu G, Wong-Staal F and Li QX: Development
of new RNAi therapeutics. Histol Histopathol. 22:211–217.
2007.PubMed/NCBI
|
